Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery


Cite item

Full Text

Abstract

This prospective, randomized, multicenter trial evaluated the risks of death, increased surgical site bleeding, gastrointestinal bleeding, acute renal failure, and allergic reactions, with ketorolac vs diclofenac or ketoprofen administered according to their approved parenteral and oral dose duration of treatment. Patients were followed for 30 days after surgery. It was concluded that ketorolac is as safe as ketoprofen and diclofenac for the treatment of pain major surgery.

About the authors

J. B Forrest

University, Hamilton, Canada

F. Camu

Vrije Universiteit, Brussel

I. A Greer

University of Glasgow

H. Kehlet

University of CopenHagen

M. Abdalla

LondonSchool of Hydlene and Tropical Medicine

F. Bonnet

Hopital Tenon, Paris, France

S. Ebrahim

University of Bristol, UK

G. Escolar

University of Barcelona, Barcelona

J. Jage

Univesitat Mainz

S. Pocock

London School of Hydlene and Tropical Medicine

G. Velo

University of Verona

M. Langman

Birmingham University

G. Bianchi Porro

University Hospital, Milan

M. M Samama

University Hopital-Dieu de Paris

E. Heitlinge

Ckdt Communications Ltd, Allschwill, Switzerland

References

  1. Kenny G.N. Potential renal, haematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs. 1992; 44 (Suppl 5): S31-37.
  2. Souter A.J. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg. 1994; 79: 1178-1190.
  3. Gales B.J., Gales M.A. Death associated with inappropriate ketorolac dosing. Ann Pharmacother. 1995; 29: 1299.
  4. Fleming B.M., Coombs D.W. Bleeding diathesis after perioperative ketorolac. Anesth Analg. 1991; 73: 235.
  5. Quan D.J., Kayser S.R. Ketorolac-induced acute renal failure following a single dose. J Toxicol Clin Toxicol. 1994; 32: 305309.
  6. Summers K., Wilson R. The management of drug safety in the new Europe: ketorolac, a case study. Pharmaceutical Med. 1994; 8: 135-143.
  7. Strom B.L., Berlin J.A., Kinman J.L. et al. Parenteral ketorolac and the risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996; 275: 376-382.
  8. Forrest J. Nonsteroidal anti-inflammatory drugs (NSAIDs). Anesth Clinics N Am: Ann Anesth Pharmacol 1997; 1: 179-204.
  9. Langman M.J. Risks of anti-inflammatory drug-associated damage. Inflamm Res. 1999; 48: 236-238.
  10. Kehlet H., Dahl J.B. Are perioperative nonsteroidal antiinflammatory drugs ulcerogenic in the short-term. Drugs. 1992; 44 (Suppl 5): S38-41.
  11. Willett L.R., Carson J.L., Strom B.L. Epidemiology of gastrointestinal damage associated with nonsteroidal antiinflammatory drugs. Drug Safety. 1994; 10: 170-181.
  12. Garcia Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal antiinflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998; 158: 33-39.
  13. Langman M.J. Epidemiology of nonsteroidal anti-inflammatory drug damage to stomach and duodenum. Ital J Gastroenterol Hepatol. 1999; 33 (Suppl 1): S2-S5.
  14. Bricker S.R.W., Savage M.E., Hanning C.D. Perioperative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1987; 4: 429-434.
  15. Wierod F.S., Frandsen N.J., Jacobsen J.D., Hartvigsen A., Olsen P.R. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol. 1998; 321: 20-22.
  16. Conrad K.A., Fagan T.C., Mackie M.J., Mayshar P.V. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther. 1988; 43: 542-546.
  17. Antiplatelet Trialist Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: 81106.
  18. Mismetti P., Laporte S., Darmon J.-Y., Buchmiiller A., Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001; 88: 913-930.
  19. Greer I.A., Gibson J.L., Young A., Johnstone J., Walker I.D. Effect of ketorolac and low-molecular weight heparin individually and in combination on haemostasis. Blood Coagul Fibrinolysis. 1999; 10: 367-373.
  20. Sharma S., Chang D.W., Koutz C., Evans G.R., Robb G.L., Langstein H.N., Kroll S.S. Incidence of hematoma associated with ketorolac after TRAM flap breast reconstruction. Plast Reconstr Surg. 2001; 107: 352-355.
  21. Harris K. The role of prostaglandins in the control of renal function. Br. J. Anaesth. 1992; 69: 233-235.
  22. Pearce C.J., Gonzalez F.M., Wallin J.D. Renal failure and hyperkalemia associated with ketorolac tromethamine. Arch Intern Med. 1993; 153: 1000-1002.
  23. Feldman H.I., Kinman J.L., Berlin J.A. et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med. 1997; 126: 193-199.
  24. Lee A., Cooper M.G., Craig J.C., Knight J.F., Keneally J.P. The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on postoperative renal function: a meta-analysis. Anaesth Intens Care. 1999; 27: 574-580.
  25. Power I. Aspirin-induced asthma. Br J Anaesth. 1993; 71: 619-21
  26. Chen A.H., Bennett C.R. Ketorolac-induced bronchospasm in an aspirin-intolerant patient. Anesth Prog. 1994; 41: 102-107.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies